We seek to improve the efficacy of a promising anticancer agent, taxol, by reformulation in a carrier-based system. Ongoing clinical trials show activity of taxol in the treatment of refractory human ovarian cancer,melanoma, and others. Dose-limiting side effects of taxol include myelosuppression, non-hematologic effects such as peripheral neuropathy, and alopecia; life-threatening epithelial necrosis in the gastrointestinal (GI) tract also has been noted. In addition to toxicity of the Cremophor vehicle, taxol is given by prolonged infusion; this limits not only comfort and convenience to the patient, but, more importantly, limits the opportunities for widening the taxol therapeutic index through alterations in route and schedule of administration that could optimize taxol pharmacokinetics. Several modern drug carrier systems, including cyclodextrins, polyethylene glycols, and lipid vesicles (liposomes), presently are under evaluation to reduce dose-limiting side effects of anticancer agents. Among these carriers, liposomes represent a mature, versatile technology for improved solubilization of lipophilic drugs such as adriamycin (ADR), Amphotericin B, and cyclosporine. ADR:liposome formulations have been examined in Phase I human trials, and show a reduction in ADR toxic side effects, particularly myelosuppression, epithelial necrosis in the GI tract, and alopecia. Human pharmacokinetic studies also reveal a reduction in biotransformation of liposome-encapsulated ADR to a metabolite believed to be inactive. Thus the reduced toxicity observed in clinical trials suggest the feasibility of further dose escalation for AFR reformulated in a liposome carrier system, as well as a prolonged circulation time for active drug. We propose to develop carrier formulations of taxol, with the primary aim of eliminating the toxic effects attributed to the Cremophor vehicle, and the secondary aim of modulating the toxicity, and perhaps the pharmacology, of taxol itself. First priority is given to optimizing formulations of taxol:liposomes already identified in preliminary studies; second priority is given to developing new-generation carrier formulations such as taxol:cyclodextrins, which may be more amenable to large-scale pharmaceutical production, and which may possess additional unique pharmacological properties. The development scheme first will evaluate cytostatic and cytotoxic potency of taxol formulations in vitro, on human ovarian cancer cell lines, and a murine melanoma and colon carcinoma. Sexond, we will optimize antitumor activity of the taxol:carrier formulations in murine tumor systems, and subsequently evaluate efficacy against a human ovarian tumor in athymic nude mice. Third, we will examine whether carrier formulations alter the pharmacokinetics and tissue distribution of active taxol.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA055251-01
Application #
3199744
Study Section
Special Emphasis Panel (SRC (42))
Project Start
1991-09-01
Project End
1994-08-31
Budget Start
1991-09-01
Budget End
1992-08-31
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
State University of New York at Buffalo
Department
Type
Schools of Pharmacy
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Yang, Jun; Mager, Donald E; Straubinger, Robert M (2010) Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J 12:1-10
Zhou, Rong; Mazurchuk, Richard V; Tamburlin, Judith H et al. (2010) Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. J Pharmacol Exp Ther 332:479-88
Straubinger, Robert M; Krzyzanski, Wojciech; Francoforte, Crystal M et al. (2007) Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development. Anticancer Res 27:1237-46
Straubinger, Robert M; Arnold, Robert D; Zhou, Rong et al. (2004) Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res 24:397-404
Fetterly, Gerald J; Straubinger, Robert M (2003) Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 5:E32
Fetterly, G J; Tamburlin, J M; Straubinger, R M (2001) Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. Biopharm Drug Dispos 22:251-61
Campbell, R B; Balasubramanian, S V; Straubinger, R M (2001) Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J Pharm Sci 90:1091-105
Campbell, R B; Balasubramanian, S V; Straubinger, R M (2001) Phospholipid-cationic lipid interactions: influences on membrane and vesicle properties. Biochim Biophys Acta 1512:27-39
Zhou, R; Balasubramanian, S V; Kahl, S B et al. (1999) Biopharmaceutics of boronated radiosensitizers: liposomal formulation of MnBOPP (manganese chelate of 2,4-(alpha, beta-dihydroxyethyl) deuterioporphyrin IX) and comparative toxicity in mice. J Pharm Sci 88:912-7
Mazurchuk, R; Zhou, R; Straubinger, R M et al. (1999) Functional magnetic resonance (fMR) imaging of a rat brain tumor model: implications for evaluation of tumor microvasculature and therapeutic response. Magn Reson Imaging 17:537-48

Showing the most recent 10 out of 18 publications